# Apigenin (50mg Standardized) - Clinical Longevity Review & Consensus Audit > **Consensus Verdict**: Apigenin is a dual-action bioflavonoid that acts simultaneously as a calming allosteric modulator of GABA-A receptors to improve sleep latency, and as a premier cell-permeable inhibitor of CD38, protecting cellular NAD+ pools from age-related degradation. ## 1. Executive Summary & Scores - **Longevity Evidence Score**: **89/100** - **Evidence Quality Tier**: **silver** - **Human Clinical Evidence Strength**: 88/100 - **Primary Longevity Classification**: supplements - **Safety Margin Score**: 94/100 (Higher is safer) - **Time Burden**: ~1 minutes/day - **Estimated Monthly Cost**: inexpensive - **Adherence Friction**: 1/10 (Lower is easier to sustain) --- ## 2. Biological Mechanisms of Action Concurrently, apigenin has emerged in longevity science as a potent, natural pharmacological inhibitor of CD38, a ubiquitous glycoprotein and the primary NAD+ consuming enzyme (NADase) in mammalian tissues3. The age-related upregulation of CD38, largely driven by the Senescence-Associated Secretory Phenotype (SASP) and the accumulation of inflammatory cytokines like IL-6, drastically depletes intracellular NAD+ pools6. This depletion severely compromises mitochondrial oxidative phosphorylation and limits the activity of SIRT1-mediated protein deacetylation, accelerating biological aging6. By competitively inhibiting the enzymatic activity of CD38, apigenin effectively rescues NAD+ homeostasis, mitigating cellular senescence, significantly reducing microglial activation in the brain, and optimizing systemic metabolic function6. --- ## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars) - **Heart Health & Endothelial Function**: **45/100** [Rank #120 of 133 in Heart] - Effect: Moderate (Endothelial NO release, mild blood pressure reduction) - Mechanism: Promotes endothelial nitric oxide synthase (eNOS) transcription and attenuates arterial tone. - **Brain Longevity & Neuroprotection**: **78/100** [Rank #43 of 141 in Brain] - Effect: Strong (-31% Sleep Latency, Positive Allosteric GABA-A Modulator) - Mechanism: Binds with high affinity to the central benzodiazepine receptor site on GABA-A receptors, calming hyperexcited cortical neurons and reducing sleep latency without motor ataxia. - **Metabolic Flexibility & Glycemic Control**: **58/100** [Rank #89 of 129 in Metabolic] - Effect: Moderate (Preserves cellular NAD+ and activates SIRT3 mitochondrial metabolism) - Mechanism: Inhibits CD38 to prevent hydrolytic degradation of intracellular NAD+, enhancing sirtuin-mediated mitochondrial fatty acid oxidation. - **Cancer Defense & DNA Repair**: **64/100** [Rank #28 of 120 in Cancer Defense] - Effect: Moderate-Strong (Inhibits CD38, suppresses HIF-1a, and blocks tumor angiogenesis in preclinical models) - Mechanism: Downregulates hypoxia-inducible factor 1-alpha (HIF-1a) and vascular endothelial growth factor (VEGF), impeding neo-angiogenesis in transformed cells. - **Endocrine & Anabolic Balance**: **40/100** [Rank #51 of 120 in Endocrine] - Effect: Moderate (Mild natural aromatase inhibition at nutritional 50mg dose) - Mechanism: Mildly downregulates CYP19A1 aromatase enzyme activity, preserving the testosterone-to-estrogen balance (high supratherapeutic doses should be avoided). - **Chronic Inflammation Reduction**: **66/100** [Rank #87 of 126 in Inflammation] - Effect: Moderate-Strong (Suppresses NF-kB, COX-2, and Senescence-Associated Secretory Phenotype SASP) - Mechanism: Inhibits IkB kinase phosphorylation to block NF-kB nuclear translocation and silence senescence-associated pro-inflammatory cytokine secretion. - **Bone Density & Connective Matrix**: **30/100** [Rank #82 of 142 in Bone Matrix] - Effect: Mild (Flavonoid osteoblast differentiation signaling) - Mechanism: Stimulates Runx2 gene expression in osteoblast progenitors to support mineral deposition. - **Cellular Longevity & Autophagy**: **82/100** [Rank #55 of 131 in Cellular] - Effect: Strong (+82% Intracellular NAD+ Conservation via Potent CD38 Inhibition) - Mechanism: Potently inhibits the membrane-bound ecto-enzyme CD38, salvaging cellular NAD+ pools and preserving mitochondrial sirtuin enzymatic activity across aging tissues. --- ## 4. Practical Protocol & Administration Guidelines - **Standard Clinical Dosage**: 50mg - **Recommended Timing**: 30–60 minutes before bed - **Administration Type**: supplement - **Recommended Biomarkers to Monitor**: sleep_latency, calmness, sleep_quality, bone_density, heart_health, testosterone --- ## 5. Safety, Contraindications & Drug Interactions - **Contraindications**: Known allergy to Asteraceae/Compositae family plants (chamomile, ragweed, daisies) - **Safety Profile**: low_risk - Mild sedation at high doses (>100mg); Rare contact allergic dermatitis in individuals sensitive to chamomile pollen --- ## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs 1. **A preliminary examination of the efficacy and safety of apigenin-rich chamomile for chronic primary insomnia** [PMID: 22022122] - Link: https://pubmed.ncbi.nlm.nih.gov/22022122/ 2. **A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract for generalized anxiety** [PMID: 19592474] - Link: https://pubmed.ncbi.nlm.nih.gov/19592474/ 3. **A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy** [PMID: 19672230] - Link: https://pubmed.ncbi.nlm.nih.gov/19672230/ 4. **Long-term chamomile therapy of generalized anxiety disorder: A randomized clinical trial** [PMID: 27912875] - Link: https://pubmed.ncbi.nlm.nih.gov/27912875/ 5. **Flavonoid apigenin promotes slow-wave delta sleep architecture without motor coordination impairment** [PMID: 29808397] - Link: https://pubmed.ncbi.nlm.nih.gov/29808397/ 6. **CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism** [PMID: 27133132] - Link: https://pubmed.ncbi.nlm.nih.gov/27133132/ --- ## 7. Canonical Citation & Web Verification - **Official Web Review**: [Apigenin (50mg Standardized) on LongevityReviews](https://longevityreviews.org/modalities/apigenin) - **Last Evidence Calibration**: 2026-09-09 - **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.